ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Bioassay Backlog To Be Cleared Up In Year: Squire

November 26, 1976

O’Conor Names DCCP Director, Says He’ll Push Development Of NCI’s Efforts In Epidemiology

April 28, 1978

DES-Breast Cancer Risk Studies Concept approved

March 7, 1986

Deluge Of SBIR Contract Proposals Changes Picture at NCI, Could Save $5 Million For Cancer

April 12, 1985

Flood Says Congress Will Renew Cancer Act, But Only After “All Out” Review of Research Policy

December 3, 1976

NIH Awards 24 More Grants For Women’s Health Initiative

October 14, 1994